Small Molecules, radiopharmaceutical imaging

Monopar Therapeutics is focused on developing innovative radiopharmaceuticals aimed at treating advanced solid tumors and Wilson Disease. Their lead product, MNPR-101, is designed to target the uPAR (urokinase-type plasminogen activator receptor), which is selectively expressed in tumors. This specificity allows for a personalized approach to cancer treatment, as MNPR-101 is expected to complement existing therapies rather than replace them. The company is advancing MNPR-101 through various clinical stages, including imaging and therapeutic applications, with ongoing trials to assess its efficacy in combination with established chemotherapies and other treatment modalities.

In addition to its oncology pipeline, Monopar has in-licensed ALXN1840, a late-stage investigational drug for Wilson Disease, showcasing its commitment to addressing rare diseases. The company leverages its expertise in drug development to navigate the complexities of regulatory approval and commercialization. Monopar's strategy emphasizes the importance of personalized medicine, aiming to enhance treatment outcomes through targeted therapies that align with the unique characteristics of individual cancers and patient needs.

United States

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers. 

Cancer

Monopar Therapeutics

Wilson's disease

ALXN1840 (tiomolybdate choline) 

Soft tissue sarcoma

Camsirubicin

Small Molecule Pharmaceuticals

Solid tumor/s

MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against the urokinase plasminogen activator receptor (uPAR). PET imaging studies in preclinical xenograft models of triple-negative breast, colorectal, and pancreatic cancers displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors. The imaging results, along with corresponding in vivo efficacy studies with actinium-225 (Ac-225, a powerful alpha-emitting therapeutic radioisotope) bound to MNPR-101 in preclinical xenograft tumor models, support the development MNPR-101 as a targeted radiopharmaceutical for multiple advanced cancer indications.

MNPR-101-Zr

MNPR-101-RIT

MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary first-in-class humanized monoclonal antibody MNPR-101, which is highly selective against the urokinase plasminogen activator receptor (uPAR).&nbsp;

Monopar Therapeutics

Company Details